Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS: Safestyle suffers amid "difficult" trading conditions

Wed, 27th Sep 2023 13:10

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Safestyle UK PLC - Bradford-based retailer and manufacturer of PVCu replacement windows and doors - Revenue in half-year ended July 2 declines 5.3% on-year to GBP74.1 million from GBP78.3 million. Pretax loss widens to GBP6.7 million from GBP2.8 million. Decides against interim dividend, after 0.4 pence per share payout a year prior. "The trading context of the UK economy and consumer confidence remains extremely difficult. Encouragingly, inflation is beginning to show some signs of moderating, but that follows a period of sustained high inflation. The impact of significantly higher interest rates than expected is clearly impacting consumers' disposable income," Safestyle says.

----------

Zegona Communications PLC - London-based company focused on communications and entertainment opportunities - Pretax loss in six months to June narrows slightly to EUR1.8 million from EUR1.9 million. Generates no revenue, unchanged year-on-year. Zegona adds: "Over the last 6 months we have continued to focus on identifying and pursuing the right opportunity within the European telecommunications market where we can again successfully apply our proven "buy-fix-sell" strategy to generate attractive returns for our shareholders. We remain patient and disciplined in our approach and are encouraged by the stabilisation in both the economic outlook and telecommunications market trends, which contribute to the confidence we have in our ability to find the right next investment for Zegona." On Friday, it confirmed it was in talks with Vodafone Group PLC to acquire its Spanish operations. Zegona said the deal remains subject to agreement on final terms with Vodafone, completion of its due diligence and formalisation of funding arrangements. As a result, it stressed that there is "no certainty" that the potential acquisition will go ahead, nor as to any of the final terms if a deal were to be struck.

----------

ProBiotix Health PLC - Wakefield, England-based life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions - Pretax loss in six months to June 30 widens to GBP512,000 from GBP251,000 a year prior. It reports "other administrative costs" more than double to GBP668,000 from GBP274,000. Revenue rises 83% to GBP552,000 from GBP302,000. Chief Executive Officer Steen Andersen says: "Since I took over as CEO in January 2023, my focus has been on building and developing a defined strategy whereby we are looking to become a solutions provider of finished probiotic products in consumer formats. My objective is to build ProBiotix into a GBP10 million plus turnover company, marketing our products both under our own brands and partner private labels. We are excited about the future of the company and remain committed to providing long term value to our shareholders."

----------

OptiBiotix Health PLC - York, England-based life sciences company, which develops edible compounds to tackle chronic conditions like obesity and diabetes - Swings to pretax loss of GBP1.9 million in first six months of 2023, from profit of GBP13.9 million a year prior. In the prior year, it booked a GBP21.6 million profit on the disposal of a subsidiary. It registers no such gains this time around. Revenue rises to GBP351,000 from GBP119,000. CEO Stephen O'Hara says: "The aim for the second half of the year is to maintain our focus on managing costs, growing sales and closing out ongoing discussions with a number of larger partners across first and second-generation products to ensure a return on investment from the expansion of our commercial and business development teams."

----------

Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Revenue in year ended June 30 falls 16% to GBP61.0 million from GBP72.8 million. Allergy's pretax loss stretches to GBP49.8 million from GBP12.7 million. "This financial year has been challenging, however, the group has made good progress in recovering manufacturing capacity and developing robust quality systems that are well-placed to support future growth," CEO Manuel Llobet says.

----------

Fadel Partners Inc - media rights and royalty management software developer - Revenue in half-year ended June 30 declines 20% to USD5.4 million from USD6.7 million a year earlier. Pretax loss widens to USD1.3 million from USD1.1 million. CEO Tarek Fadel says: "The outlook for Fadel remains positive and the benefits of our investments are already coming through as the strong trading momentum enjoyed in 1H23 continues into the second half of the year. Investments made in the business to date, alongside the wider shift towards digitisation, are driving increased demand for our offering and give great confidence in the group's outlook."

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.